Back to search results

Comparing Imaging Systems for Inherited Retinal Disease

This study is comparing two newer ultrawide field cameras, Clarus and Optos, to a standard imaging system called Spectralis. The goal is to see if Clarus and Optos can provide the same useful information as Spectralis for evaluating and monitoring inherited retinal diseases (IRDs). Researchers will compare the retinal patterns seen with each camera. You may be able to join if you are 18 or older and have a clinical or genetic diagnosis of an IRD. This study is currently unclear on its recruitment status and plans to enroll 50 participants.

Study design
This is an interventional study comparing three different imaging devices in 50 participants.
What's involved
You will have your pupils dilated and photographs taken of the inside of your eyes using three different cameras. This will take up to 2 hours.
Compensation
Not stated in the trial record.
Follow-up
The comparisons between imaging systems will be measured up to 2 hours after the imaging is completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06380075

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

Recruiting
NAAges 18+Interventional
University of Wisconsin, Madison
~50 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Spectralis FAF imagingOptos imagingClarus imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Compare FAF retinal patterns by Clarus and standard Spectralis FAF imaging
Measured over Up to 2 hours
+3 more outcomes measured

Conditions

Retinal Disease

Explore related trials

Hereditary nephropathy

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Kimberly Stepien, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Angie Adler
[email protected]
608-265-7557
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants 18 years and older with a clinical and/ or genetic diagnosis of IRD recruited either from the clinic and/or the Inherited Ocular Disease Registry to participate in this trial
Participants that are willing to participate as evidenced by signing the written informed consent

Exclusion

Presence of ocular conditions other than an IRD which may affect the quality of ocular imaging including but not limited to advanced cataracts, corneal disorders, nystagmus, vitreous hemorrhage, or poor dilation
Presence of ocular conditions other than an IRD which may affect interpretation of retinal imagining including but not limited to epiretinal membrane, choroidal neovascular membrane, or macular scarring
Patients with advanced IRDs who are unable to fixate for imaging
Patients unable to tolerate ocular imaging
Patients who do not wish to participate

What this trial measures

  • Compare FAF retinal patterns by Clarus and standard Spectralis FAF imagingUp to 2 hours

    Graders will independently measure area of FAF retinal patterns from images of each device. The measurements (in mm²) will be compared between the two devices.

  • Compare FAF retinal patterns by Optos and standard Spectralis FAF imagingUp to 2 hours

    Graders will independently measure area of FAF retinal patterns from images of each device. The measurements (in mm²) will be compared between the two devices.

  • Compare FAF retinal patterns by Clarus and Optos FAF imagingUp to 2 hours

    Graders will independently measure area of FAF retinal patterns from images of each device. The measurements (in mm²) will be compared between the two devices.

  • Compare Spectralis FAF imaging to Spectralis OCT imagingUp to 2 hours

    In participants with clearly defined macular FAF retinal pattern changes, graders will independently measure area of retinal patterns from images of each device. The measurements (in mm²) will be compared between the two devices.